Compare Novartis AG (NVS) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs TotalEnergies SE — how do they compare? Novartis AG trades at $139.98 (market cap $262.64B), while TotalEnergies SE trades at $91.46 (market cap $200.03B). The key difference: Novartis AG is the larger of the two by market cap, and TotalEnergies SE pays the higher dividend (4.7%). Which is the better fit depends on your goals.
| NVS | TTE | |
|---|---|---|
Market Cap | $262.64B | $200.03B |
Sector | Health | Energy |
52-Week High | $168.62 | $93.60 |
52-Week Low | $121.80 | $57.39 |
Enterprise Value | $303.97B | $231.02B |
Dividend Yield | 3.44% | 4.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
TotalEnergies (TTE) trades at $90.1, up 1.7% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $98. Recent earnings show a beat in Q2 2026, and the company is advancing key LNG projects in Papua New Guinea and Angola. Cash flow improved to a positive $358 million in 2025, though revenue has declined from 2022 peaks.
The outlook is positive given analyst support and strategic investments, but risks include volatile oil prices and execution challenges. The stock offers value with a P/E of 11.28 and a 9.08% net margin, supported by a strong dividend history. Investors should weigh growth initiatives against energy market cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
